Fuerjia: Multiple institutions including Guosheng Securities Co., Ltd. and Xinyuan Fund Management Co., Ltd. conducted research on our company on March 11.

Securities Star News, on March 11, 2026, Furjia (301371) announced that Guosheng Securities Co., Ltd. Wang Changlong, Zhou Mingrui; Xinyuan Fund Management Co., Ltd. Yao Qifan, Wang Yaxuan; China Life Asset Management Co., Ltd. Zhu Shuangjing, Zhou Weiye; Founder Securities Co., Ltd. Gu Hanqing; CITIC Construction Investment Securities Co., Ltd. Liu Lewen conducted a survey of our company.

The specific content is as follows:

Q: Does the company have any new raw material reserves in 2025?

A: Currently, the company has filed for 5 new raw materials, of which 2 were filed in 2025, namely “Aurefyl Tripeptide-129 Amide” and “Acetyl Tyrosyl Cyclo-D-Glu Tripeptide-110 Amide.” The specific raw material filing information can be checked on the National Medical Products Administration website. The company will develop products based on new raw materials in the future to further improve the product matrix.

Q2: Based on public data, the company’s online performance in January and February was good. How do you forecast this year’s performance?

In 2025, the company optimized offline sales channels and improved the management team, laying a solid foundation for business development in 2026. The company is prepared and confident about 2026, hoping for good performance both online and offline. The specific results will depend on the company’s actual operational data in 2026. Please stay tuned.

Q3: How is the progress of the company’s three types of recombinant collagen injection products?

Currently, the company’s recombinant type III humanized collagen lyophilized fibers have completed clinical trials and obtained clinical trial summary reports, and are preparing submission materials. The recombinant type III humanized collagen gel for injection aims to start clinical trials this year. The company will actively disclose relevant progress according to regulatory rules. Please continue to follow.

Q4: How are the company’s offline sales channels divided?

Currently, the company’s offline sales channels are mainly divided into professional channels, CS channels, K channels, and OTC channels.

Q5: The company’s net profit margin fluctuated significantly in 2025. Will it recover this year?

Due to the company’s proactive offline sales channel optimization, there will be short-term impacts on offline revenue and profit. Offline net profit margin is higher than online. The company will actively expand offline channels this year, hoping for good offline performance to contribute positively to overall revenue and net profit margin. The actual performance in 2026 will depend on the company’s operations and results. Please stay tuned.

Q6: Does the company have ODM sales business?

Currently, all products are sold under the company’s own brand “Furjia,” and there is no external ODM sales business involved.

Q7: What are the company’s plans for dividend payout this year?

The company’s dividend plan has not yet been determined. Please stay tuned for the announcement to be disclosed on April 23, 2026. The company always maintains a proactive attitude toward investors, actively conducts cash dividends, and shares its benefits and achievements with investors. The specific dividend amount will depend on the company’s operating performance in 2025 and capital planning for 2026.

Furjia (301371) main business: production and sales of cosmetics and medical devices.

Furjia’s 2025 Q3 report shows that in the first three quarters, the company’s main revenue was 1.297 billion yuan, a decrease of 11.54% year-on-year; net profit attributable to shareholders was 325 million yuan, down 36.73%; non-recurring net profit was 254 million yuan, down 48.2%. In Q3 2025, the company’s single-quarter main revenue was 434 million yuan, down 17.58%; net profit attributable to shareholders was 95.39 million yuan, down 44.96%; non-recurring net profit was 87.42 million yuan, down 47.3%. The debt ratio is 3.6%, investment income is 24.3675 million yuan, financial expenses are -27.7628 million yuan, and gross profit margin is 81.11%.

In the past 90 days, one institution has given a rating of “Buy” for this stock.

Below is detailed profit forecast information:

Margin financing and securities lending data show that in the past 3 months, net financing outflow was 13.6238 million yuan, with a decrease in financing balance; net securities lending inflow was 241,400 yuan, with an increase in securities lending balance.

The above content is compiled from public information by Securities Star, generated by AI algorithms (Network Credit Number 310104345710301240019), and does not constitute investment advice.